Your browser doesn't support javascript.
loading
Early monitoring of infliximab serum trough levels predicts long-term therapy failure in patients with axial spondyloarthritis.
Martínez-Feito, A; Navarro-Compán, V; Hernández-Breijo, B; Olariaga-Mérida, E; Peiteado, D; Villalba, A; Nuño, L; Monjo, I; Diego, C; Pascual-Salcedo, D; Nozal, P; Balsa, A; Plasencia-Rodríguez, C.
Afiliación
  • Martínez-Feito A; Immunology Unit, La Paz University Hospital, Madrid, Spain.
  • Navarro-Compán V; Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research, Madrid, Spain.
  • Hernández-Breijo B; Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research, Madrid, Spain.
  • Olariaga-Mérida E; Rheumatology Department, La Paz University Hospital, Madrid, Spain.
  • Peiteado D; Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research, Madrid, Spain.
  • Villalba A; Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research, Madrid, Spain.
  • Nuño L; Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research, Madrid, Spain.
  • Monjo I; Rheumatology Department, La Paz University Hospital, Madrid, Spain.
  • Diego C; Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research, Madrid, Spain.
  • Pascual-Salcedo D; Rheumatology Department, La Paz University Hospital, Madrid, Spain.
  • Nozal P; Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research, Madrid, Spain.
  • Balsa A; Rheumatology Department, La Paz University Hospital, Madrid, Spain.
  • Plasencia-Rodríguez C; Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research, Madrid, Spain.
Scand J Rheumatol ; 51(2): 102-109, 2022 Mar.
Article en En | MEDLINE | ID: mdl-34182885
OBJECTIVE: To evaluate whether serum infliximab trough levels (ITL) during the early stages of treatment are predictive of long-term clinical failure in patients with axial spondyloarthritis (axSpA). METHODS: Longitudinal observational study involving 81 patients with axSpA monitored during infliximab therapy. Serum ITL were measured before starting infliximab treatment and at weeks 2 (W2), W6 and W12 of treatment. Disease activity was assessed by Ankylosing Spondylitis Disease Activity Score (ASDAS) at baseline, W24 and W52, and every 6 months thereafter until treatment discontinuation, regardless of the reason. Non-clinically important improvement was defined by ΔASDAS<1.1. The association between serum levels during the early stages and clinical outcomes (non-clinically important improvement at W52, drug survival and drop-out due to secondary inefficacy) was investigated through logistic regression models and Kaplan Meier curves. Receiver operating characteristic (ROC) curves were employed to determine the best cut-off for serum ITL. RESULTS: Out of the 81 patients, 45 (56%) did not achieve clinical improvement at W52. These patients had lower serum ITL at W12 compared to those who improved: ITL [median (IQR)]: 4.1(0.9-8.3) µg/mL vs 7.1 (4.3-11.3) µg/mL, respectively;p = 0.007). ITL<6.7 µg/mL at W12 was significantly associated with: i) not achieving clinical improvement at W52 (OR: 2.3; 95%CI: 1.3-3.9); ii) shorter drug survival (5.0 years (95% CI 3.8-6.2) vs 7.0 years (95% CI 4.8-6.9; p = 0.04), and iii) higher drop-out rates due to secondary inefficacy (OR: 3.5; 95% CI: 1.2-10.2). CONCLUSION: Low serum ITL at W12 were associated with long-term clinical failure in patients with axSpA, due to secondary inefficacy.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Espondilitis Anquilosante / Espondiloartritis / Espondiloartritis Axial Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Scand J Rheumatol Año: 2022 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Espondilitis Anquilosante / Espondiloartritis / Espondiloartritis Axial Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Scand J Rheumatol Año: 2022 Tipo del documento: Article País de afiliación: España